rs2011077

A SNP in the FGFR4 gene on chromosome 5. Its most notable genotype is C;C: In Japanese, 6.2x increased risk of developing prostate cancer, a 3x increased risk of developing BPH, and a 5.5x increased risk of developing metastatic prostate cancer

Gene
FGFR4
Location
Chr 5177,094,455 (GRCh38)
Highest magnitude
3.0Important
Tested on
23andMe, AncestryDNA, FamilyTreeDNA
Minor allele frequency
25%

Genotypes

Plus strand, as in 23andMe and AncestryDNA files.

  1. T;TGoodNormal risk of developing prostate cancer, BPH, and metastatic prostate cancerMinor · 1.010% of people
  2. C;TBadIn Japanese, 2.4x risk of prostate cancer, 1.7x increased risk of BPH, and 1.5x increased risk of developing metastatic prostate cancerTypical · 0.028% of people
  3. C;CMost notableBadIn Japanese, 6.2x increased risk of developing prostate cancer, a 3x increased risk of developing BPH, and a 5.5x increased risk of developing metastatic prostate cancerImportant · 3.062% of people

SNPedia records rs2011077 on the minus strand: (A;A), (A;G), (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Frequency

Share of each genotype in 11 HapMap populations.

  • AverageT;T 10% C;T 28% C;C 62%
  • European ancestry (Utah)T;T 4% C;T 32% C;C 65%
  • Han Chinese (Beijing)T;T 23% C;T 59% C;C 18%
  • Japanese (Tokyo)T;T 33% C;T 48% C;C 20%
  • Yoruba (Nigeria)T;T 0% C;T 5% C;C 95%
  • African ancestry (Southwest US)T;T 0% C;T 7% C;C 93%
  • Chinese (Denver)T;T 28% C;T 49% C;C 23%
  • Gujarati IndianT;T 3% C;T 42% C;C 55%
  • Luhya (Kenya)T;T 0% C;T 6% C;C 95%
  • Mexican ancestry (Los Angeles)T;T 14% C;T 33% C;C 53%
  • Maasai (Kenya)T;T 0% C;T 3% C;C 97%
  • TuscanT;T 2% C;T 26% C;C 73%

Conditions, medicines and genes

Other FGFR4 SNPs

All FGFR4 SNPs

Notes

From SNPedia

Show notes, about 210 words

A study of ~500 Japanese prostate cancer patients found that individuals with a rs2011077(G;G) genotype had a 6.2- and 3-fold increased risk of prostate cancer and benign prostate hyperplasia (BPH), and a 5.5-fold increased risk of metastatic prostate cancer, compared to the (A;A) genotype.

C;T

For the rs2011077 polymorphism, a significant increased risk of prostate cancer was found in men with the GG genotype (aOR = 6.260, 95% CI = 3.152–12.433, p < 0.001) or the GA genotype (aOR = 2.497, 95% CI = 1.717–3.630, p < 0.001) compared with the AA genotype. When GG, GA and AA genotypes were valued as 2, 1 and 0, respectively, the presence of the G allele was shown to increase the risk of prostate cancer with a gene dosage effect (aOR = 2.500, 95% CI = 1.871–3.339, p < 0.001). As for BPH, a significantly increased risk was found in the GG genotype (aOR = 3.033, 95% CI = 1.352–6.807, p = 0.007) and the GA genotype (aOR = 1.700, 95% CI = 1.077–2.683, p = 0.023) compared with the AA genotype. When GG, GA and AA genotypes were valued as 2, 1 and 0, respectively, the presence of the G allele was shown to increase the risk of BPH with a gene dosage effect (aOR = 1.724, 95% CI = 1.218–2.441, p = 0.002).

C;C

see discussion at rs2011077

Source and license

Adapted from rs2011077 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.